1Goebel F, Yakovlev A, Pozniak AL,et al.Short-term antivial activity of TMC278-a novel NNRTI-in treatment-naive HIV-1-infected subjects[J]. AIDS, 2006, 20(13): 1721-1726.
2Grinsztejn B, Nguyen BY, Katlama C,et al.Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatmentexperienced patients with multidrugresistant virus:a phase Ⅱ randomised controlled trial[J]. Lancet, 2007, 369:1261-1269.
3Lataillade M, Kozal MJ. The hunt for HIV-1 integrase inhibitors[J]. AIDS Patient Care STDS, 2006, 20: 489-501.
4Markowitz M, Nguyen BY, Gotuzzo N. Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment Naive Patients With HIV-1 Infection:Results of a 48 Week Controlled Study[J]. J Acquir Immune Defic Syndr, 2007, 46(2): 125-133.
5Jan Munch, Ludger Standker, Knut Adermann, et al. Discovery and Optimization of a Natural HIV-1 Entry Inhibitor Targeting the gp41 Fusion Peptide[J]. Cell, 2007, 129: 263-275.
6Si Z, Madani N, Cox JM, et al. Small-molecule inhibitors of HIV-1 entry block recep tor-induced conformational changes in the viralenvelope glycop roteins[J]. Proc Natl Acad Sci USA, 2004, 101:5036-5041.
7MontembaultM, Vo-Thanh G, Deyine A, et al. A possible improvement for structure-based drug design illustrated by the discovery of a Tat HIV-1 inhibitor [J]. Bioorg Med Chem Lett, 2004, 14(6): 1543-1546.
8F, Lori, A. Foli, L.M. et al. Virostatics: A New Class of Anti-HIV Drugs Current Medicinal Chemistry, 2007, 14: 233-241.
9Pozniak, A. L. Tenofovir disoproxil fumarate emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antirelroviral-naive patients. J. Aquir[J]. Immune Defic, 2006, 43, 535-540.
